0.15Open0.15Pre Close0 Volume5 Open Interest2.00Strike Price0.00Turnover1837.72%IV2.87%PremiumAug 16, 2024Expiry Date0.09Intrinsic Value100Multiplier-1DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.6644Delta1.4431Gamma13.93Leverage Ratio-2.9830Theta0.0000Rho9.26Eff Leverage0.0001Vega
Caribou Biosciences Stock Discussion
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
No comment yet